Table 1.

Summary of Published Cases of Biopsy-Confirmed AA-Amyloid Kidney Disease in Patients With Rheumatoid Arthritis Treated With Tocilizumab and Reported Outcomes

Reference	Age (y)	Sex	Presentation	Treatment Dose (mg/kg/mo)	Treatment Duration (mo)	Concurrent Treatment	Response
Vinicki et al (2013)45	48	F	5.0 g/24 h proteinuria	8	24	None	0.5 g proteinuria/24 h
Matsui et al (2014)46	60	F	Progressive kidney dysfunction	8	36	None	Persistent deposition on biopsy, progression to kidney failure
Yamada et al (2014)47	71	F	Nephrotic syndrome, 4.3 g/24 h proteinuria	8	10	Losartan	Resolved proteinuria at 3 mo
Courties et al (2015)44	52	F	9.0 g/24 h proteinuria	8	8	Glucocorticoids	Progression to kidney failure within 20 mo
	70	F	8.4 g/24 h proteinuria	8	3	Glucocorticoids	Stable eGFR, 0.5 g/24 h proteinuria
	47	M	10.0 g/24 h proteinuria	8	6	Colchicine	Progression to kidney failure within 6 mo
	80	F	4.0 g/24 h proteinuria	8	34	Glucocorticoids	Improved eGFR, progression to 6.0 g/24 h proteinuria
	80	F	2.1 g/24 h proteinuria	8	32	Glucocorticoids	Stable eGFR, 0.09 g/24 h proteinuria
	73	M	8.0 g/24 h proteinuria	8	6	Glucocorticoids	Stable eGFR, 4.7 g/24 h proteinuria
Iijima et al (2015)48	51	F	Nephrotic syndrome, 5.2 g/24 h proteinuria and RPGN	8	18	None	Improved eGFR, 1.2 g/24 h proteinuria
Yamagata et al (2017)49	67	F	Urinary protein excretion of 7.5 g per gram urinary creatinine	Not reported	10	None	0.5 g/24 h proteinuria
Fukuda et al (2020)50	59	F	Nephrotic syndrome, 6.5 g/24 h proteinuria	8	24	None	1.1g/24 h proteinuria
	71	M	0.06 g/24 h proteinuria	8	60	None	Glomerular amyloid deposits unchanged on repeat biopsy (at 2 y)

Abbreviations: AA, serum amyloid A protein; eGFR, estimated glomerular filtration rate; F, female; M, male; RPGN, rapidly progressive glomerulonephritis.